Bellco Capital

Bellco Capital operates as a direct investment firm, strategically deploying capital to foster and back nascent companies. The firm adopts a science-first approach, channeling resources into innovative ventures, particularly within the biotechnology sector, while also engaging in significant investments in specialized biotech real estate. Its core strategy involves nurturing entities poised for substantial expansion and market influence.

The firm was established in 2003 by Rebecka Belldegrun, M.D., and Arie Belldegrun, M.D., FACS. Arie Belldegrun brings a distinguished background from the pharmaceutical industry, having co-founded and led prominent biotech companies. This deep-rooted industry expertise and financial acumen formed the foundational insight for Bellco Capital, positioning it as a strategic partner for scientific advancements.

Bellco Capital primarily serves early-stage and growth-oriented companies seeking capital and strategic guidance to achieve rapid development. The firm’s vision centers on identifying and empowering enterprises with groundbreaking scientific potential, aiming to transform innovative concepts into impactful market realities. It is focused on building enduring value within the life sciences ecosystem.